AU2022360009A1 - Influenza vaccines - Google Patents

Influenza vaccines Download PDF

Info

Publication number
AU2022360009A1
AU2022360009A1 AU2022360009A AU2022360009A AU2022360009A1 AU 2022360009 A1 AU2022360009 A1 AU 2022360009A1 AU 2022360009 A AU2022360009 A AU 2022360009A AU 2022360009 A AU2022360009 A AU 2022360009A AU 2022360009 A1 AU2022360009 A1 AU 2022360009A1
Authority
AU
Australia
Prior art keywords
amino acid
seq
acid sequence
polypeptide
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022360009A
Other languages
English (en)
Inventor
Benedikt ASBACH
George CARNELL
Matteo Ferrari
Simon Frost
Jonathan Luke Heeney
Sneha VISHWANATH
Ralf Wagner
David Wells
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Enterprise Ltd
Diosynvax Ltd
Original Assignee
Cambridge Enterprise Ltd
Diosynvax Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2114328.4A external-priority patent/GB202114328D0/en
Priority claimed from GBGB2208070.9A external-priority patent/GB202208070D0/en
Priority claimed from GBGB2213958.8A external-priority patent/GB202213958D0/en
Application filed by Cambridge Enterprise Ltd, Diosynvax Ltd filed Critical Cambridge Enterprise Ltd
Publication of AU2022360009A1 publication Critical patent/AU2022360009A1/en
Assigned to CAMBRIDGE ENTERPRISE LIMITED, DIOSYNVAX LTD reassignment CAMBRIDGE ENTERPRISE LIMITED Request for Assignment Assignors: DIOSYNVAX LTD, THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE, UNIVERSITÄT REGENSBURG
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022360009A 2021-10-06 2022-10-06 Influenza vaccines Pending AU2022360009A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB2114328.4 2021-10-06
GBGB2114328.4A GB202114328D0 (en) 2021-10-06 2021-10-06 Influenza vaccines
GBGB2208070.9A GB202208070D0 (en) 2022-05-31 2022-05-31 Influenza vaccines
GB2208070.9 2022-05-31
GBGB2213958.8A GB202213958D0 (en) 2022-09-23 2022-09-23 Influenza vaccines
GB2213958.8 2022-09-23
PCT/GB2022/052534 WO2023057766A1 (en) 2021-10-06 2022-10-06 Influenza vaccines

Publications (1)

Publication Number Publication Date
AU2022360009A1 true AU2022360009A1 (en) 2024-05-23

Family

ID=83692952

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022360009A Pending AU2022360009A1 (en) 2021-10-06 2022-10-06 Influenza vaccines

Country Status (6)

Country Link
US (1) US20240408190A1 (https=)
EP (1) EP4412644A1 (https=)
JP (1) JP2024537250A (https=)
AU (1) AU2022360009A1 (https=)
CA (1) CA3234653A1 (https=)
WO (1) WO2023057766A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202004825D0 (en) * 2020-04-01 2020-05-13 Diosynvax Ltd Influenza vaccines
GB202315888D0 (en) * 2023-10-17 2023-11-29 Diosynvax Ltd Influenza vaccines
WO2026018213A1 (en) * 2024-07-18 2026-01-22 Vaxthera Sas A broadly protective mosaic vaccine against highly pathogenic avian influenza viruses
WO2026074282A1 (en) * 2024-10-01 2026-04-09 Diosynvax Ltd. Influenza vaccines

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR083533A1 (es) * 2010-10-22 2013-03-06 Boehringer Ingelheim Vetmed Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe
WO2013075266A1 (en) * 2011-11-23 2013-05-30 Vacdiagn Biotechnology Co., Ltd. Immune methods against influenza viruses and combinatorial vaccines thereof
EP2814837B1 (en) * 2012-02-13 2017-11-29 University of Pittsburgh - Of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for human and avian h5n1 influenza
TW201729835A (zh) 2015-10-22 2017-09-01 現代公司 呼吸道病毒疫苗
EP3852799A4 (en) * 2018-09-21 2022-10-05 Board of Regents of the University of Nebraska METHODS FOR THE PRODUCTION AND USE OF UNIVERSAL CENTRALIZED FLU VACCINE GENES

Also Published As

Publication number Publication date
CA3234653A1 (en) 2023-04-13
WO2023057766A1 (en) 2023-04-13
EP4412644A1 (en) 2024-08-14
US20240408190A1 (en) 2024-12-12
JP2024537250A (ja) 2024-10-10

Similar Documents

Publication Publication Date Title
US20240408190A1 (en) Influenza vaccines
AU676258B2 (en) Nucleic acid pharmaceuticals
CN107574156A (zh) 类病毒组合物颗粒及其使用方法
CN116113431A (zh) 冠状病毒疫苗
EP2061887B1 (en) Vlp based influenza vaccine delivery system
US9284356B2 (en) Identification of a west nile virus CD4 T cell epitope and use thereof
US20230149530A1 (en) Influenza vaccines
WO2021220246A1 (en) Recombinant sars-cov-2 polypeptides and uses
KR20150036685A (ko) 약독화된 돼지 인플루엔자 백신 및 이의 제조 방법 및 용도
Dupuy et al. Directed molecular evolution improves the immunogenicity and protective efficacy of a Venezuelan equine encephalitis virus DNA vaccine
US20250312437A1 (en) Coronavirus vaccines
CA2498770C (en) Infectious hepacivirus pseudo-particles containing functional e1, e2 envelope proteins
WO2023275538A1 (en) Beta-coronavirus vaccines
CN111867625B (zh) 具有失活ul18和/或ul8的新ehv
KR102335524B1 (ko) 뉴캐슬병 바이러스 벡터 기반 pten 유전자 삽입 재조합 뉴캐슬병 바이러스를 이용한 뇌종양 치료용 암용해바이러스 및 이를 이용한 뇌종양 치료용 조성물
EP1992358A1 (en) Aids vaccine based on replicative vaccinia virus vector
KR102910531B1 (ko) 내열성이 개선된 뉴캐슬병 바이러스 및 이를 포함하는 뉴캐슬병 바이러스 백신
WO2026074282A1 (en) Influenza vaccines
CN118922204A (zh) 流感疫苗
KR20230109702A (ko) 최적화된 보편적 인플루엔자 백신의 설계, 이들의 설계 및 용도
WO2025083402A1 (en) Coronavirus vaccines
CN117210496A (zh) 一种新型冠状病毒的免疫原及其应用
WO2021048402A1 (en) Lassavirus vaccines

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: DIOSYNVAX LTD

Free format text: FORMER APPLICANT(S): DIOSYNVAX LTD; THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE; UNIVERSITAET REGENSBURG

Owner name: CAMBRIDGE ENTERPRISE LIMITED

Free format text: FORMER APPLICANT(S): DIOSYNVAX LTD; THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE; UNIVERSITAET REGENSBURG